Undervalued Criteria in the Evaluation of Multimodal Trials for Upper GI Cancers

REFERENCES

• Siewert JR, Stein HJ, Feith M, Brücher BLDM, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons learned from more than 1000 consecutive resections at a single centre in the western world. Ann Surg 2001;234(3):360–369.
   PubMed Web of Science ®Google Scholar
• Stein HJ, Feith M, Brücher BLDM, Nährig J, Siewert JR. Early esophageal squamous cell and adenocarcinoma: Pattern of lymphatic spread and prognostic factors for long term survival after surgical resection. Ann Surg 2005;242(4):566–573.
   PubMed Web of Science ®Google Scholar
• Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998;85:1457–1459.
   PubMed Web of Science ®Google Scholar
• Lauren T. The two histological main types of gastric carcinoma (1965). Acta Pathol Microbiol Scand 64:31–49.
   PubMedGoogle Scholar
• Halperin EC, Perez CA, Brady LW. Principles and Practice of Radiation Oncology, 5th edition. Perez and Brady's principles and practice of radiation oncology. Lippincott Williams & Wilkins, 2008.
   Google Scholar
• Brücher BLDM. Esophageal squamous cell carcinoma: pre-operative combined radiochemotherapy from a surgical oncological viewpoint. Chirurg 2009;80:1011–1018.
   PubMed Web of Science ®Google Scholar
• Esophagus and esophagogastric junction. In: AJCC cancer staging manual, 7th edition Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti AI (eds.). Springer, 2010, 103–111.
   Google Scholar
• Ectors N, Driessen A, de Hertog G, Lerut T, Geboes K. Is adenocarcinoma of the esophagogastric junction or cardia different from Barrett adenocarcinoma? Arch Pathol Lab Med 2005;128:183–185.
   Google Scholar
• Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220–241.
   PubMed Web of Science ®Google Scholar
• Shimkin MB. Contrary to Nature. Washington, DC: U.S. Department of Health, Education and Welfare, 1977.
   Google Scholar
• Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics 2005. CA Cancer J Clin 2005;55:10–30.
   PubMed Web of Science ®Google Scholar
• Siegel, R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett's Esophagus compared with the general population: a population-based Cohort study. Gastroenterology 2013;144:1375–1383.
   PubMed Web of Science ®Google Scholar
• Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality ratres and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893–1907.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon (France): IARC, 2010, Available from: http://globocan.iarc.fr.
   Google Scholar
• Website American Cancer Society: Survival rates for cancer of the esophagus by stage. 2014. http://www.cancer.org/ cancer/esophaguscancer/detailedguide/esophagus-cancer-surv ival-rates
   Google Scholar
• Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, Tsujitani S, Seto Y, Furukawa H, Oda I, Ono H, Tanabe S, Kaminishi M. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer 2013;16:1–27.
   PubMed Web of Science ®Google Scholar
• Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439–449.
   PubMed Web of Science ®Google Scholar
• Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2–8.
   PubMed Web of Science ®Google Scholar
• Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. American Cancer Society: cancer statistics, 2004. CA Cancer J Clin 2004;54:8–29.
   PubMed Web of Science ®Google Scholar
• Yang PC, Davis S. Incidence of cancer of the esophagus in the US by histologic type. Cancer 1988;61:612–617.
   PubMed Web of Science ®Google Scholar
• Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142–146.
   PubMed Web of Science ®Google Scholar
• Yang PC, Davis S. Incidence of cancer of the esophagus in the US by histologic type. Cancer 1988;61:612–617.
   PubMed Web of Science ®Google Scholar
• Blot WJ, Devesa SS, Kneller RW. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287–1289.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Clapp RW, Doos WG. The increasing frequency of adenocarcinoma of the esophagus. Cancer 1989;64:526–530.
   PubMed Web of Science ®Google Scholar
• Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 2005;54:i1–5.
   Web of Science ®Google Scholar
• Solaymani-Dodaran M, Logan RFA, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004;53:1070–1074.
   PubMed Web of Science ®Google Scholar
• Huang Q, Fang DC, Yu CG, Zhang J, Chen MH: Barrett's esophagus-related diseases remain uncommon in China. J Dig Dis 2011;12:420–427.
   PubMed Web of Science ®Google Scholar
• Schneider JH, Küper MA, Königsrainer A, Brücher BLDM. Non-acid gastroesophageal reflux measured using multichannel intraluminal impedance in older patients. J Gastroinest Surg 2010;14:S17–23.
   Web of Science ®Google Scholar
• Schneider JH, Küper M, Königsrainer A, Brücher BLDM. Transient lower esophageal sphincter relaxation and consecutive esophageal motor response in humans and in an animal model. Obes Surg 2009;19:595–600.
   PubMed Web of Science ®Google Scholar
• Schneider JME, Brücher BLDM, Küper M, Saemann K, Königsrainer A, Schneider JH. Multichannel intraluminal impedance measurement of gastro-esophageal reflux in patients with different stages of morbid obesity. Obes Surg 2009;19:1522–1529.
   PubMed Web of Science ®Google Scholar
• Hampel HH, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143:199–211.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005;100:1243–1250.
   PubMed Web of Science ®Google Scholar
• Küper MA, Kratt T, Kramer MK, Zdichavsky M, Schneider JH, Glatzle J, Stüker D, Konigsrainer A, Brücher BLDM. Effort, safety, and findings of routine preoperative endoscopic evaluation of morbidity obese patients undergoing bariatric surgery. Surg Endosc 2010;24:1996–2001.
   PubMed Web of Science ®Google Scholar
• Kasama K, Mui W, Lee WJ, Lakdawala M, Naitoh T, Seki Y, Sasaki A, Wakabayashi G, Sasaki I, Kawamura I, Kow L, Frydenberg H, Chen A, Narwaria M, Chowbey P. IFSO-APC consensus statement 2011. Obes Surg 2012;22:677–684.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Tsuji I, Tamakoshi A, Matsuo K, Ito H, Wakai K, Nagata C, Mizoue T, Sasazuki S, Inoue M, Tsugane S. Research group for the development and evaluation of cancer prevention strategies in Japan: obesity and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Oncol 2012;42:212–221.
   PubMedGoogle Scholar
• Marshall BJ. The pathogenesis of non-ulcer dyspepsia. Med J Aust 1985;143:319.
   PubMed Web of Science ®Google Scholar
• Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55:2111–2115.
   PubMed Web of Science ®Google Scholar
• Azuma T. Review Helicobacter pylori CagA protein variation associated with gastric cancer in Asia. J Gastroenterol 2004;39:97–103.
   PubMed Web of Science ®Google Scholar
• Matsuhisa T, Aftab H. Observation of gastric mucosa in Bangladesh, the country with the lowest incidence of gastric cancer, and Japan, the country with the highest incidence. Helicobacter 2012;17:396–401.
   PubMedGoogle Scholar
• Gaddy JA, Radin JN, Loh JT, Zhang F, Washington MK, Peek Jr RM, Algood HMS, Cover TL. High Dietary Salt Intake Exacerbates Helicobacter pylori-Induced Gastric Carcinogenesis. Infect Immun 2013;81:2258–2267.
   Google Scholar
• Ruffato A, Mattioli S, Perrone O, Lugaresi M, Di Simone MP, D'Errico A, Malvi D, Aprile MR, Raulli G, Frassineti L. Esophagogastric metaplasia relates to nodal metastases in adenocarcinoma of esophagus and cardia. Ann Thorac Surg 2013;95:1147–1153.
   PubMed Web of Science ®Google Scholar
• Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol 2013;107:230–236.
   PubMed Web of Science ®Google Scholar
• Anderson WF, Camargo MC, Fraumeni JF Jr, Correa P, Rosenberg PS, Rabkin CS. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 2010;303:1723–1728.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Thiagarajan P, Jankowski JA. Why is there a change in patterns of GE cancer? Recent Results Cancer Res 2012;196:115–140.
   PubMedGoogle Scholar
• Lee JH, Kim KM, Cheong JH, Noh SH. Current management and future strategies of gastric cancer. Yonsei Med J 2012;53:248–257.
   Google Scholar
• Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662–1669.
   PubMed Web of Science ®Google Scholar
• Brücher BLDM, Stein HJ, Bartels H, Feussner H, Siewert JR. Achalasia and Esophageal Cancer: Incidence, Prevalence and Prognosis. World J Surg 2011;25:745–749.
   Google Scholar
• Corning HK. Lehrbuch der Entwicklungsgeschichte des Menschen. 2.Auflage. JF Bergmann Verlag Muenchen, 1925.
   Google Scholar
• Clara M. Entwicklungsgeschichte des Menschen. 5.Auflage. G Thieme Verlag Leipzig 1955.
   Google Scholar
• Langmann J. Medizinische Embryologie. 7.Auflage. Georg Thieme Verlag Stuttgart 1985.
   Google Scholar
• Kubik S. Embryologie und Anatomie des Oesophagus. In Aktuelle Therapie des Oesophaguscarcinoms, Langhans, Schreiber, Haering, Reding, Siewert Buente (eds.). Berlin Heidelberg: Springer Verlag, 1990.
   Google Scholar
• O'Rahilly R, Müller F. Human Embryology & Teratology. 3rd edition. Chichester, Weinheim, Brisbane, Singapore, Toronto: Wiley-Liss New York, 2001.
   Google Scholar
• Graham A, Okabe M, Quinlan R. The role of the endoderm in the development and evolution of the pharyngeal arches. J Anat 2005;207:479–487.
   PubMed Web of Science ®Google Scholar
• Spence JR, Lauf R, Shroyer NF. Vertebrate intestinal endoderm development. Dev Dyn 2001;240:501–520.
   Google Scholar
• Wells JM, Melton DA. Vertebrate endoderm development. Annu Rev Cell Dev Biol 1999;15:393–410.
   PubMed Web of Science ®Google Scholar
• Swift GH, Liu Y, Rose SD, Bischof LJ, Steelman S, Buchberg AM, Wright CV, MacDonald RJ. An endocrine-exocrine switch in the activity of the pancreatic homeodomain protein PDX1 through formation of a trimeric complex with PBX1b and MRG1 (MEIS2). Mol Cell Biol 1998;18:5109–5120.
   PubMed Web of Science ®Google Scholar
• Siewert JR, Feith M, Stein HJ. Esophagectomy as therapeutic principle for squamous cell esophageal cancer. Chirurg 2005;76:1033–1044.
   PubMed Web of Science ®Google Scholar
• Brücher BLDM, Stein HJ, Werner M, Siewert JR. Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer 2001;92:2228–2233.
   PubMed Web of Science ®Google Scholar
• Liebermann-Meffert D. Anatomical basis for the extent and surgical approach to esophageal cancer. Dis Esoph 2001;14: 81–87.
   PubMed Web of Science ®Google Scholar
• Liebermann-Meffert D, Stein HJ. Anatomy of the esophagus. In: Shackelford's Surgery of the Alimentary Tract. 6th edition, J Peters (ed.). WB Saunders, Philadelphia USA. 2005.
   Google Scholar
• Law S, Wong KH, Kwok KF, Chu KM, Wong J. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg 2004;240:791–800.
   PubMed Web of Science ®Google Scholar
• McGregor DH, Mills G, Boudet RA. Intramural squamous cell carcinoma of the esophagus. Cancer 1976;37:1556–1561.
   PubMed Web of Science ®Google Scholar
• Von Rahden BHA, Brücher BLDM, Sarbia M. Esophageal Squamous Cell Carcinoma with entirely Intramural Growth Pattern. Virchows Archiv 2006;448:862–866
   PubMed Web of Science ®Google Scholar
• Ebihara Y, Hosokawa M, Kondo S, Katoh H. Thirteen cases with intramural metastasis to the stomach in 1259 patients with oesophageal squamous cell carcinoma. Eur J Cardiothorac Surg 2004;26:1223–1225.
   PubMed Web of Science ®Google Scholar
• Koide N, Yazawa K, Koike S, Adachi W, Amano J, Ishii K. Two cases of gastric involvement of esophageal cancer: intramural metastasis and intramural lymph node metastasis. Hepatogastroenterology 1998;45:1619–1623.
   PubMed Web of Science ®Google Scholar
• Brücher BLDM, Piso P, Verwaal V, Esquivel J, Deraco M, Yonemura Y, Gonzalez-Moreno S, Pelz J, Königsrainer A, Ströhlein M, Levine EA, Morris D, Bartlett D, Glehen O, Garofalo A, Nissan A. Peritoneal carcinomatosis: overview and basics. Cancer Invest 2012;30:209–224.
   PubMed Web of Science ®Google Scholar
• Roviello F, Caruso S, Neri A, Marrelli D. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. Eur J Surg Oncol 2013;39:1309–1316.
   PubMed Web of Science ®Google Scholar
• Kitajima M, Kitagawa Y. Surgical treatment of esophageal cancer–the advent of the era of individualization. N Engl J Med 2002;347:1705–1709.
   PubMed Web of Science ®Google Scholar
• Kelsen D. Preoperative chemoradiotherapy for esophageal cancer. J Clin Oncol 2001;19:283–285.
   PubMed Web of Science ®Google Scholar
• Brücher BLDM, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmermann F, Molls M, Höfler H, Siewert JR. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006;106:2119–2127.
   PubMed Web of Science ®Google Scholar
• Brücher BLDM, Stein HJ, Zimmermann F, Werner M, Sarbia M, Busch R, Dittler HJ, Molls M, Fink U, Siewert JR. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 2004;30:963–971.
   PubMed Web of Science ®Google Scholar
• Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538–543.
   PubMed Web of Science ®Google Scholar
• Malthaner RA, Wong RK, Rumble RB, Zuraw L. Members of the gastrointestinal cancer disease site group of cancer care ontario's program in evidence-based care: neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004;2:35.
   PubMed Web of Science ®Google Scholar
• Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxì A, Cammà C. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925–930.
   PubMed Web of Science ®Google Scholar
• Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086–1092.
   PubMed Web of Science ®Google Scholar
• Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310–2317.
   PubMed Web of Science ®Google Scholar
• Lorenzen S, Brücher BLDM, Zimmermann F, Geinitz H, Riera J, Schuster T, Roethling N, Höfler H, Ott K, Peschel C, Siewert JR, Molls M, Lordick F. Neoadjuvant infusion 5-fluorouracil and escalating doses of oxaliplatin given weekly with concurrent radiation in locally advanced esophageal squamous cell carcinoma: results of a phase I / II trial. Br J Cancer 2008;99:1020–1026.
   PubMed Web of Science ®Google Scholar
• Greil R, Stein HJ. Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer? Lancet Oncol 2007;8:189–190.
   PubMed Web of Science ®Google Scholar
• Malthaner RA, Collin S, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database System Rev 2006;3:CD001556.
   PubMedGoogle Scholar
• Wang C, Ding T, Chang L. [A randomized clinical study of preoperative chemotherapy for esophageal carcinoma]. Zhonghua Zhong Liu Za Zhi 2001;23:254–255.
   PubMedGoogle Scholar
• Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988;96:242–248.
   PubMed Web of Science ®Google Scholar
• Roth JA. Squamous cell cancer of the esophagus. Treatment concept at the Houston MD Anderson Cancer Center. Chirurg 1992;63:683–688.
   PubMed Web of Science ®Google Scholar
• Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A, Mäntyla M, Modig H, Munck-Wikland E, Rosengren B, Tausjø J, Elgen K. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16:1104–1109.
   PubMed Web of Science ®Google Scholar
• Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 1992;127:1446–1450.
   PubMedGoogle Scholar
• Schlag P. Randomized study of preoperative chemotherapy in squamous cell cancer of the esophagus. CAO Esophageal Cancer Study Group. Chirurg 1992;63:709–714.
   Google Scholar
• Maipang T, Vasinanukorn P, Petpichetchian C, Chamroonkul S, Geater A, Chansawwaang S, Kuapanich R, Panjapiyakul C, Watanaarepornchai S, Punperk S. Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol 1994;56:191–197.
   PubMed Web of Science ®Google Scholar
• Ancona E, Ruol A, Chiarion-Sileni V, Santi S, Baldan N, Buin F, Prospective randomized trial of preoperative chemotherapy versus surgery alone in operable squamous cell carcinoma of the esophagus. Preliminary report on response to chemotherapy, pre- and postoperative morbidity and mortality [Studio prospettico randomizzato di chemioterapia neoadiuvante versus sola chirurgia nel cancro operabile (T2–3, ogni N, M0) dell'esofago. Valutazione della risposta alla chemioterapia e della morbilita e mortalita pre e postoperatorie]. Acta Chirurgica Italica 1995;51:308–317.
   Google Scholar
• Bhansali MS, Vaidya JS, Bhatt RG, Patil PK, Badwe RA, Desai PB. Chemotherapy for carcinoma of the esophagus: a comparison of evidence from meta-analyses of randomized trials and of historical control studies. Ann Oncol 1996;7:355–359.
   PubMed Web of Science ®Google Scholar
• Kok TC, van Lanschot J, Siersema PD, van Overhagen H, Tilanus HW. Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: final report of a phase III multicenter randomized controlled trial. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1997;17:A984.
   Google Scholar
• Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. Thoracic Cardiovasc Surg 1997;114:210–217.
   Web of Science ®Google Scholar
• Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979–1984.
   PubMed Web of Science ®Google Scholar
• Kelsen DP, Winter KA, Gunderson LI, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG; Radiation Therapy Oncology Group; USA Intergroup. Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer [Long–Term results of RTOG Trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer]. J Clin Oncol 2007;25:3719–3725.
   PubMed Web of Science ®Google Scholar
• Baba M, Natsugoe S, Shimada M, Nakano S, Shirao K, Kusano C, Fukumoto T, Aikou T. Does preoperative chemotherapy cause adverse effects on the perioperative course of patients undergoing esophagectomy for carcinoma? Jpn J Thoracic Cardiovasc Surg 1999;47:199–203.
   PubMedGoogle Scholar
• Baba M, Natsugoe S, Shimada M, Nakano S, Kusano C, Fukumoto T, Aikou T, Akazawa K. Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus. Dis Esophagus 2000;13: 136–41.
   PubMed Web of Science ®Google Scholar
• Fietkau R. No improvement of prognosis by neoadjuvant chemotherapy alone in operable esophageal carcinoma [Keine Verbesserung der Prognose des operablen Osophaguskarzinoms durch eine alleinige neoadjuvante Chemotherapie]. Strahlentherapie und Onkologie 1999;175:251–252.
   PubMedGoogle Scholar
• Clark P. Medical Research Council (MRC) randomized phase III trial of surgery with or without pre-operative chemotherapy in resectable cancer of the oesophagus. [Abstract] Br J Cancer 2000;83:A-CT2, 1.
   Google Scholar
• Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L, Peracchia A. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91:2165–2174.
   PubMed Web of Science ®Google Scholar
• Wang C, Ding T, Chang L. A randomized clinical study of preoperative chemotherapy for esophageal carcinoma. Zhonghua Zhong Liu Za Zhi 2001;23:254–255.
   PubMedGoogle Scholar
• Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 2002;359:1727–1733.
   PubMed Web of Science ®Google Scholar
• Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002;183:274–279.
   PubMed Web of Science ®Google Scholar
• Hohenberger W. Surgical resection with or without preoperative chemotherapy in esophageal cancer: a randomized controlled trial [German]. Strahlentherapie und Onkologie 2003;179:271–272.
   Web of Science ®Google Scholar
• Stilidi I, Bokhyan V, Tryakin A, Suleymanov E, Kononets P, Malikhova O, Tjulandin S. Preoperative chemotherapy followed by resection vs. surgery alone for locally advanced esophageal carcinoma: interim analysis of a randomized study [Preoperative chemotherapy followed by resection vs. surgery alone for locally advanced esophageal carcinoma: interim analysis of a randomized study]. J Clin Oncol 2006;24:4055.
   Google Scholar
• Thirion PG, Michiels S, Le Maitre A, Tierney J. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. J Clin Oncol 2007;45:4512.
   Google Scholar
• Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta analysis. Lancet Oncol 2007;8:226–234.
   PubMed Web of Science ®Google Scholar
• Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouché O, Segol P, Bedenne L, Rougier P, Ychou M. Final results of a randomized trial comparing preoperative 5-flurouracil(F)/cisplatin (P) to surgery alone in adenocarcinoma of the stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007;25:4510.
   Google Scholar
• Teoh AY, Chiu PW, Yeung WK, Liu SY, Wong SK, Ng EK. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol 2013;24:165–171.
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MC, van Lanschot JJ Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A. CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer N Engl J Med 2012;366:2074–2084.
   PubMed Web of Science ®Google Scholar
• Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, Thomas CR Jr. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375–384.
   PubMedGoogle Scholar
• Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:481–489.
   PubMed Web of Science ®Google Scholar
• Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M. Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators: capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:490–499.
   PubMed Web of Science ®Google Scholar
• Ohno S, Tomisaki S, Oiwa H, Sakaguchi Y, Ichiyoshi Y, Maehara Y, Sugimachi K. Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. J Am Coll Surg 1995;180:577–582.
   PubMed Web of Science ®Google Scholar
• Yuasa N, Miyake H, Yamada T, Ebata T, Nimura Y, Hattori T. Clinicopathologic comparison of Siewert type II and III adenocarcinomas of the gastroesophageal junction. World J Surg 2006;30:364–371.
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810–1820.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGa): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–697. Erratum in: Lancet 2010;376:1302.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH. CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315–321.
   PubMed Web of Science ®Google Scholar
• Hiripi E, Jansen L, Gondos A, Emrich K, Holleczek B, Katalinic A, Luttmann S, Nennecke A, Brenner H, Gekid Cancer Survival Working Group. Survival of stomach and esophagus cancer patients in Germany in the early 21st century. Acta Oncol 2012;51:906–914.
   PubMed Web of Science ®Google Scholar
• Ito Y, Nakayama T, Miyashiro I, Ioka A, Tsukuma H. Conditional survival for longer-term survivors from 2000–2004 using population-based cancer registry data in Osaka, Japan. BMC Cancer 2013;13:304.
   PubMedGoogle Scholar
• Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M, Tanaka H. Epidemiology of esophageal cancer in Japan and China. J Epidemiol 2013;23:233–242.
   PubMed Web of Science ®Google Scholar
• Brücher BLDM, Swisher S, Konigsrainer S, Zieker D, Hartmann J, Stein H, Kitagawa Y, Law S, Ajani JA. Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol 2009;16:878–886.
   PubMed Web of Science ®Google Scholar
• Komanduri S, Deprez PH, Atasoy A, Hofmann G, Pokieser P, Ba-Ssalamah A, Collard JM, Wijnhoven BP, Verhage RJ, Brücher B, Schuhmacher C, Feith M, Stein H. Barrett's esophagus: treatments of adenocarcinoma I. Ann N Y Acad Sci 2011;1232:248–264.
   PubMed Web of Science ®Google Scholar
• Twaddell WS, Wu PC, Verhage RJ, Feith M, Ilson DH, Schuhmacher CP, Luketich JD, Brücher B, Vallböhmer D, Hofstetter WL, Krasna MJ, Kandioler D, Schneider PM, Wijnhoven BP, Sontag SJ. Barrett's esophagus: treatments of adenocarcinoma II. Ann N Y Acad Sci 2011;1232:265–291.
   PubMed Web of Science ®Google Scholar
• Von Rahden BH, Stein HJ, Feith M, Becker K, Siewert JR. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol 2005;23:874–879.
   PubMed Web of Science ®Google Scholar
• Möbius C, Freire, Becker I, Feith M, Brücher BL, Hennig M, Siewert JR, Stein HJ. VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg 2007;31:1768–1772.
   PubMed Web of Science ®Google Scholar
• Kitagawa Y, Ueda M, Ando N, Ozawa S, Shimizu N, Kitajima M. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 1996;2:909–914.
   PubMed Web of Science ®Google Scholar
• Sarbia M, Pühringer-Oppermann F, Brücher BLDM. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodal treated esophageal squamous cell carcinoma. Br J Cancer 2007;97:1404–1408.
   PubMed Web of Science ®Google Scholar
• Brücher BLDM, Keller G, Werner M, Müller U, Lassmann S, Cabras AD, Fend F, Busch R, Stein H, Allescher HD, Molls M, Siewert JR, Höfler H, Specht K. Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy. Int J Colorectal Dis 2009;24:69–77.
   PubMed Web of Science ®Google Scholar
• Mathe EA, Ngyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson AG, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009;15:6192–6200.
   PubMed Web of Science ®Google Scholar
• Bandla S, Pennathur A, Luketich JD, Beer DG, Lin L, Bass AJ, Godfrey TE, Litle VR. Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. Ann Thorac Surg 2012;93:1101–1106.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhao LQ, Xiong MM, Wang XQ, Yang GR, Qiu ZL, Wu M, Liu ZH. Gene expression profiles at different stages of human esophageal squamous cell carcinoma. World J Gastroenterol 2003;9:9–15.
   PubMed Web of Science ®Google Scholar
• Ziogas DE, Roukos DH. Limitations of isolated tumor cells in gastric cancer: heterogeneity requests systems biology approaches towards personalized medicine. Ann Surg Oncol 2010;17:343–344.
   PubMed Web of Science ®Google Scholar
• He Y, Wu J, Dressman DC, Iacobuzio-Donahue C, Markowitz SD, Velculescu VE, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N. Heteroplasmic mitochondrial DNA mutations in normal and tumor cells. Nature 2010;464:610–614.
   PubMed Web of Science ®Google Scholar
• Longo DL. Tumor heterogeneity and personalized medicine. N Engl J Med 2012;366:956–957.
   PubMed Web of Science ®Google Scholar
• Brücher BLDM, Jamall IS. Epistemology of the origin of cancer: a new paradigm. BMC Cancer 2014;14:331.
   PubMed Web of Science ®Google Scholar
• Brücher BLDM, Lyman G, van Hillegersberg R, Pollock RE, Lordick F, Yang HK, Ushijima T, Yeoh KG, Skricka T, Polkowski W, Wallner G, Verwaal V, Garofalo A, D'Ugo D, Roviello F, Steinau HU, Wallace TJ, Daumer M, Maihle N, Reid III TJ, Ducreux M, Kitagawa Y, Knuth A, Zilberstein B, Steele SR, Jamall IS. Imagine a world without cancer. BMC Cancer 2014;14: 186.
   PubMed Web of Science ®Google Scholar